Zatz Roberto, Romão João Egídio
Renal Division, Department of Clinical Medicine, Faculty of Medicine, University of São Paulo, Av. Dr. Arnaldo 455, CEP 01246-903 São Paulo, SP, Brazil.
Ren Fail. 2006;28(8):627-9. doi: 10.1080/08860220600925685.
Brazil is the fifth largest and the fifth most populous nation in the world. Its economy rivals Mexico as the strongest in Latin America and ranks among the 15 largest economies in the world. Despite these achievements, a substantial fraction of the Brazilian population still lives in poverty, and many still have limited access to medical assistance. There are currently about 380 patients on hemodialysis per million populations (pmp), approximately one third of the U.S. prevalence, suggesting that a large fraction of end-stage renal disease (ESRD) patients are not diagnosed and treated properly. In Brazil, access to renal replacement therapy (RRT), including renal transplantation, is universal, and the corresponding costs, including those of medications (immunosuppressors and treatment of ESRD complications), are covered by the Brazilian government. However, given the continuous growth of the ESRD population and of the costs incurred by RRT, the efficacy and reach of this system may be severely limited in years to come. In the current struggle against the ESRD epidemics, the Brazilian medical community and health authorities face a triple challenge: to limit the incidence of renal disease, slow or detain the progression of established chronic nephropathies, and ensure that access to quality RRT remains granted to all those who, despite all efforts, reach ESRD.
巴西是世界上面积第五大、人口第五多的国家。其经济与墨西哥不相上下,是拉丁美洲最强大的经济体之一,跻身世界前15大经济体之列。尽管取得了这些成就,但仍有相当一部分巴西人口生活在贫困之中,许多人获得医疗救助的机会仍然有限。目前,每百万人口中约有380名患者接受血液透析,约为美国患病率的三分之一,这表明很大一部分终末期肾病(ESRD)患者没有得到正确的诊断和治疗。在巴西,包括肾移植在内的肾脏替代治疗(RRT)可普遍获得,相应费用,包括药物(免疫抑制剂和ESRD并发症治疗)费用,均由巴西政府承担。然而,鉴于ESRD患者数量的持续增长以及RRT产生的费用,该系统的疗效和覆盖范围在未来几年可能会受到严重限制。在当前对抗ESRD流行的斗争中,巴西医学界和卫生当局面临三重挑战:限制肾病发病率,减缓或阻止已确诊的慢性肾病的进展,并确保所有尽管尽了一切努力仍发展为ESRD的患者能够继续获得优质的RRT。